Evidence map›Paper›PMID 20042608›Full record

ArticleThe Journal of biological chemistry2010

Receptor interacting protein 3 suppresses vascular smooth muscle cell growth by inhibition of the phosphoinositide 3-kinase-Akt axis.

Qian Li, Geng Li, Xiaomei Lan, Ming Zheng, Kuang-Hueih Chen, Chun-Mei Cao, Rui-Ping Xiao

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Necroptosis in cardiovascular disease - a new therapeutic target.Journal of molecular and cellular cardiology · 2018
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. p55γ functional mimetic peptide N24 blocks vascular proliferative disorders.Journal of molecular medicine (Berlin, Germany) · 2015
    Article
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Qian LiInstitute of Cardiovascular Sciences, Peking University, 100083 Beijing; Institute of Molecular Medicine, Peking University, 100871 Beijing, China.
Geng LiInstitute of Cardiovascular Sciences, Peking University, 100083 Beijing.
Xiaomei LanInstitute of Cardiovascular Sciences, Peking University, 100083 Beijing; Institute of Molecular Medicine, Peking University, 100871 Beijing, China.
Ming ZhengInstitute of Molecular Medicine, Peking University, 100871 Beijing, China.
Kuang-Hueih ChenLaboratory of Cardiovascular Science, NIA, National Institutes of Health, Baltimore, Maryland 21224.
Chun-Mei CaoInstitute of Molecular Medicine, Peking University, 100871 Beijing, China. Electronic address: Caochunmei@pku.edu.cn.
Rui-Ping XiaoInstitute of Cardiovascular Sciences, Peking University, 100083 Beijing; Institute of Molecular Medicine, Peking University, 100871 Beijing, China; Laboratory of Cardiovascular Science, NIA, National Institutes of Health, Baltimore, Maryland 21224. Electronic address: Xiaor@grc.nia.nih.gov.
Peking University · CNNational Institutes of Health · US

Funding

Intramural NIH HHS
6 · The paper itself

Abstract

Proliferation of vascular smooth muscle cells (VSMCs) is a primary mechanism underlying cardiovascular proliferative disorders. Phosphoinositide 3-kinase (PI3K)-Akt (or protein kinase B) axis has been assigned at the center of pathways that regulate cell proliferation. Here we demonstrate that enhanced PI3K-Akt signaling by mitogenic stimulation or arterial injury profoundly elevates expression of receptor interacting protein 3 (RIP3) in primary cultured rat VSMCs and in vivo and that the up-regulation of RIP3 leads to VSMC growth arrest and apoptosis via inhibiting the PI3K-Akt signaling pathway, thereby alleviating balloon injury-induced neointimal formation. Specifically, mitogenic stimulation with platelet-derived growth factor-BB or angiotensin II leads to a profound increase in RIP3 expression, which is abolished by inhibition of PI3K or Akt, and increased PI3K-Akt signaling by expression of a constitutively active PI3K mutant also elevates RIP3 expression. Importantly, adenoviral overexpression of RIP3 not only triggers apoptosis but also causes cell cycle arrest at G(1)/G(0) phases that is associated with suppressed Akt activation. In sharp contrast, RIP3 gene silencing enhances serum- and platelet-derived growth factor-induced cell proliferation and Akt activation. In vivo adenoviral gene delivery of rat RIP3 (rRIP3) increased apoptosis and reduced VSMC proliferation, thus, effectively alleviating balloon injury-induced neointimal formation. The growth-suppressive and pro-apoptotic effects are independent of rRIP3 Ser/Thr kinase activity, because overexpression of a kinase-inactive mutant of rRIP3, similar to its wild type, is sufficient to induce growth arrest and apoptosis. These findings reveal a novel growth-suppressive action of RIP3, marking RIP3 as an important factor to prevent excessive mitogenic stimulation- or injury-induced vascular smooth muscle cells hyperplasia.

Indexed as

Gene Expression Regulation, EnzymologicPhosphoinositide-3 Kinase InhibitorsAnimalsApoptosisCarotid ArteriesCell ProliferationEnzyme InhibitorsMaleModels, BiologicalMuscle, Smooth, VascularMutationProto-Oncogene Proteins c-aktRatsRats, Inbred WKYReceptor-Interacting Protein Serine-Threonine KinasesSignal TransductionEnzyme InhibitorsPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktReceptor-Interacting Protein Serine-Threonine Kinases

Identifiers

PMID20042608
PMCPMC2843204
OpenAlexW2006492414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.